Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients

Anupama U. Nookala, James Crismale, Thomas Schiano, Helen Te, Joseph Ahn, Suzanne Robertazzi, Colleen Rodigas, Rohit Satoskar, K. C. Mandip, Mohamed Hassan, Coleman Smith

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis C (HCV) remains the single most common etiology of end-stage liver disease leading to simultaneous liver/kidney transplant (SLKT) and has worse post-transplant survival compared to non-HCV patients. We aim to assess the effectiveness and tolerance of the all-oral direct-acting antiviral (DAA) agents with or without ribavirin (RBV) in the treatment of HCV recurrence post-SLKT. Thirty-four patients were studied retrospectively, composed predominantly of treatment-naïve (73.5%) non-Caucasian (61.8%) males (82.4%) infected with genotype 1a (64.7%). 94.1% reached a sustained virologic response (SVR) after 24 weeks (32/34 patients), without difference between 12 and 24 weeks of therapy. 64.7% had no clinical side effects. Three deaths occurred, all unrelated to treatment. One patient had liver rejection; tacrolimus was increased and prednisone was initiated while HCV treatment was continued and the patient ultimately achieved SVR. No liver graft losses. No kidney rejection or losses. We demonstrated that DAA combinations with or without RBV result in a remarkable SVR rate and tolerated in the majority of the studied SLKT patients. It is safe to wait to treat until post–kidney transplant and therefore increase the donor pool for these patients. Our cohort is ethnically diverse, making our results generalizable.

Original languageEnglish (US)
Article numbere13198
JournalClinical Transplantation
Volume32
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Hepatitis C
Antiviral Agents
Transplants
Liver
Kidney
Ribavirin
Therapeutics
End Stage Liver Disease
Tacrolimus
Prednisone
Transplant Recipients
Genotype
Tissue Donors
Recurrence
Sustained Virologic Response

Keywords

  • direct-acting antiviral therapy
  • hepatitis C
  • liver/kidney transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients. / Nookala, Anupama U.; Crismale, James; Schiano, Thomas; Te, Helen; Ahn, Joseph; Robertazzi, Suzanne; Rodigas, Colleen; Satoskar, Rohit; Mandip, K. C.; Hassan, Mohamed; Smith, Coleman.

In: Clinical Transplantation, Vol. 32, No. 3, e13198, 01.03.2018.

Research output: Contribution to journalArticle

Nookala, AU, Crismale, J, Schiano, T, Te, H, Ahn, J, Robertazzi, S, Rodigas, C, Satoskar, R, Mandip, KC, Hassan, M & Smith, C 2018, 'Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients', Clinical Transplantation, vol. 32, no. 3, e13198. https://doi.org/10.1111/ctr.13198
Nookala, Anupama U. ; Crismale, James ; Schiano, Thomas ; Te, Helen ; Ahn, Joseph ; Robertazzi, Suzanne ; Rodigas, Colleen ; Satoskar, Rohit ; Mandip, K. C. ; Hassan, Mohamed ; Smith, Coleman. / Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients. In: Clinical Transplantation. 2018 ; Vol. 32, No. 3.
@article{714b6f6225284355af9379e87faa4666,
title = "Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients",
abstract = "Hepatitis C (HCV) remains the single most common etiology of end-stage liver disease leading to simultaneous liver/kidney transplant (SLKT) and has worse post-transplant survival compared to non-HCV patients. We aim to assess the effectiveness and tolerance of the all-oral direct-acting antiviral (DAA) agents with or without ribavirin (RBV) in the treatment of HCV recurrence post-SLKT. Thirty-four patients were studied retrospectively, composed predominantly of treatment-na{\"i}ve (73.5{\%}) non-Caucasian (61.8{\%}) males (82.4{\%}) infected with genotype 1a (64.7{\%}). 94.1{\%} reached a sustained virologic response (SVR) after 24 weeks (32/34 patients), without difference between 12 and 24 weeks of therapy. 64.7{\%} had no clinical side effects. Three deaths occurred, all unrelated to treatment. One patient had liver rejection; tacrolimus was increased and prednisone was initiated while HCV treatment was continued and the patient ultimately achieved SVR. No liver graft losses. No kidney rejection or losses. We demonstrated that DAA combinations with or without RBV result in a remarkable SVR rate and tolerated in the majority of the studied SLKT patients. It is safe to wait to treat until post–kidney transplant and therefore increase the donor pool for these patients. Our cohort is ethnically diverse, making our results generalizable.",
keywords = "direct-acting antiviral therapy, hepatitis C, liver/kidney transplantation",
author = "Nookala, {Anupama U.} and James Crismale and Thomas Schiano and Helen Te and Joseph Ahn and Suzanne Robertazzi and Colleen Rodigas and Rohit Satoskar and Mandip, {K. C.} and Mohamed Hassan and Coleman Smith",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/ctr.13198",
language = "English (US)",
volume = "32",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Direct-acting antiviral regimens are safe and effective in the treatment of hepatitis C in simultaneous liver–kidney transplant recipients

AU - Nookala, Anupama U.

AU - Crismale, James

AU - Schiano, Thomas

AU - Te, Helen

AU - Ahn, Joseph

AU - Robertazzi, Suzanne

AU - Rodigas, Colleen

AU - Satoskar, Rohit

AU - Mandip, K. C.

AU - Hassan, Mohamed

AU - Smith, Coleman

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Hepatitis C (HCV) remains the single most common etiology of end-stage liver disease leading to simultaneous liver/kidney transplant (SLKT) and has worse post-transplant survival compared to non-HCV patients. We aim to assess the effectiveness and tolerance of the all-oral direct-acting antiviral (DAA) agents with or without ribavirin (RBV) in the treatment of HCV recurrence post-SLKT. Thirty-four patients were studied retrospectively, composed predominantly of treatment-naïve (73.5%) non-Caucasian (61.8%) males (82.4%) infected with genotype 1a (64.7%). 94.1% reached a sustained virologic response (SVR) after 24 weeks (32/34 patients), without difference between 12 and 24 weeks of therapy. 64.7% had no clinical side effects. Three deaths occurred, all unrelated to treatment. One patient had liver rejection; tacrolimus was increased and prednisone was initiated while HCV treatment was continued and the patient ultimately achieved SVR. No liver graft losses. No kidney rejection or losses. We demonstrated that DAA combinations with or without RBV result in a remarkable SVR rate and tolerated in the majority of the studied SLKT patients. It is safe to wait to treat until post–kidney transplant and therefore increase the donor pool for these patients. Our cohort is ethnically diverse, making our results generalizable.

AB - Hepatitis C (HCV) remains the single most common etiology of end-stage liver disease leading to simultaneous liver/kidney transplant (SLKT) and has worse post-transplant survival compared to non-HCV patients. We aim to assess the effectiveness and tolerance of the all-oral direct-acting antiviral (DAA) agents with or without ribavirin (RBV) in the treatment of HCV recurrence post-SLKT. Thirty-four patients were studied retrospectively, composed predominantly of treatment-naïve (73.5%) non-Caucasian (61.8%) males (82.4%) infected with genotype 1a (64.7%). 94.1% reached a sustained virologic response (SVR) after 24 weeks (32/34 patients), without difference between 12 and 24 weeks of therapy. 64.7% had no clinical side effects. Three deaths occurred, all unrelated to treatment. One patient had liver rejection; tacrolimus was increased and prednisone was initiated while HCV treatment was continued and the patient ultimately achieved SVR. No liver graft losses. No kidney rejection or losses. We demonstrated that DAA combinations with or without RBV result in a remarkable SVR rate and tolerated in the majority of the studied SLKT patients. It is safe to wait to treat until post–kidney transplant and therefore increase the donor pool for these patients. Our cohort is ethnically diverse, making our results generalizable.

KW - direct-acting antiviral therapy

KW - hepatitis C

KW - liver/kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85044630051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044630051&partnerID=8YFLogxK

U2 - 10.1111/ctr.13198

DO - 10.1111/ctr.13198

M3 - Article

VL - 32

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

M1 - e13198

ER -